Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 58Breast Neoplasms 54Lymphoma 52Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 48Lymphoma, Non-Hodgkin 46Melanoma 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 40Myelodysplastic Syndromes 39Lymphoma, Follicular 29Burkitt Lymphoma 25Hodgkin Disease 24Neoplasm Metastasis 22Recurrence 21Neoplasms 21Lymphoma, Mantle-Cell 20Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Myeloproliferative Disorders 14Lymphoma, B-Cell 14Hematologic Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Carcinoma, Renal Cell 13Triple Negative Breast Neoplasms 12

Interventions

Filgrastim 2Ciprofloxacin 2sargramostim 1pegfilgrastim 1niraparib 1fludarabine phosphate 1flt3 ligand protein 1ceftobiprole medocaril 1Vegetables 1Vancomycin 1Stem Cell Factor 1Moxifloxacin 1Methotrexate 1Gentamicins 1Epoetin Alfa 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Colistin 1Cefepime 1Amoxicillin-Potassium Clavulanate Combination 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neutropenia × Cyclophosphamide × Clear all
NCT05622058 2023-02-27

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Aileron Therapeutics, Inc.

Phase 1 Terminated
6 enrolled
Breast

Alopecia, Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡